A detailed history of Tower Research Capital LLC (Trc) transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 3,377 shares of OCUP stock, worth $3,309. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,377
Previous 3,592 5.99%
Holding current value
$3,309
Previous $5,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.19 - $2.07 $255 - $445
-215 Reduced 5.99%
3,377 $4,000
Q2 2024

Aug 13, 2024

SELL
$1.51 - $2.23 $5,713 - $8,438
-3,784 Reduced 51.3%
3,592 $5,000
Q1 2024

May 15, 2024

BUY
$1.89 - $3.27 $13,940 - $24,119
7,376 New
7,376 $14,000
Q2 2023

Aug 14, 2023

SELL
$3.63 - $6.38 $6,229 - $10,948
-1,716 Reduced 99.71%
5 $0
Q1 2023

May 09, 2023

SELL
$3.01 - $3.85 $10,179 - $13,020
-3,382 Reduced 66.27%
1,721 $6,000
Q4 2022

Feb 10, 2023

BUY
$2.04 - $3.53 $3,490 - $6,039
1,711 Added 50.44%
5,103 $18,000
Q3 2022

Nov 10, 2022

BUY
$1.82 - $2.79 $465 - $714
256 Added 8.16%
3,392 $7,000
Q2 2022

Aug 15, 2022

BUY
$1.8 - $3.25 $5,644 - $10,192
3,136 New
3,136 $6,000
Q1 2022

May 12, 2022

SELL
$2.75 - $4.39 $2 - $4
-1 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$3.4 - $5.19 $3 - $5
1 New
1 $0
Q3 2021

Nov 15, 2021

SELL
$3.84 - $5.38 $12,718 - $17,818
-3,312 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$4.24 - $6.57 $3,324 - $5,150
784 Added 31.01%
3,312 $17,000
Q1 2021

May 17, 2021

BUY
$5.7 - $13.31 $11,861 - $27,698
2,081 Added 465.55%
2,528 $15,000
Q4 2020

Feb 16, 2021

BUY
$3.76 - $8.8 $1,680 - $3,933
447 New
447 $3,000

Others Institutions Holding OCUP

About Ocuphire Pharma, Inc.


  • Ticker OCUP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,579,800
  • Market Cap $20.2M
  • Description
  • Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...
More about OCUP
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.